Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 356 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Plasma Collection Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters

NCT05365451
View directory record Official record
Conditions
Interaction, Endogenous Biomarkers
Interventions
MetFORMIN Oral Solution, Cimetidine 400 MG, Furosemide Oral Liquid Product, Probenecid 500 MG
Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 22, 2026, 11:41 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer

NCT05384769
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Liquid Biopsy, Low Dose Computed Tomography of the Chest, Survey Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
50 Years to 80 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 11:41 PM EDT
Withdrawn Early Phase 1 Interventional

Isatuximab in Lung Transplant Recipients

NCT05862766
View directory record Official record
Conditions
Antibody-mediated Rejection, Allosensitization
Interventions
Isatuximab, bone marrow biopsy
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 22, 2026, 11:41 PM EDT
Completed No phase listed Observational

Studying Pathways of Resistance in KRAS-driven Cancers

NCT05272423
View directory record Official record
Conditions
KRAS P.G12C
Interventions
FoundationOne® Liquid CDx
Diagnostic Test
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 22, 2026, 11:41 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Prostasomes as Diagnostic Tool for Prostate Cancer Detection

NCT03694483
View directory record Official record
Conditions
Prostate Cancer
Interventions
Genetic analysis for the detection of prostasomes
Diagnostic Test
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 11:41 PM EDT
Terminated No phase listed Observational

Parkinson's Disease Genetics Database

NCT00855556
View directory record Official record
Conditions
Parkinson's Disease
Interventions
blood draw
Genetic
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2015 · Synced Oct 22, 2026, 11:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Platelet Rich Plasma for Musculoskeletal Conditions

NCT07231471
View directory record Official record
Conditions
Osteoarthritis (OA), Osteoarthritis (OA) of the Knee, Osteoarthritis (OA) of the Hip, Osteoarthritis (OA) of the Shoulder, Osteoarthritis Ankle, Elbow Osteoarthritis, Epicondylitis of the Elbow, Plantar Fasciitis of Both Feet, Tendinopathy
Interventions
Platelet Rich Plasma Injection, Platelet Rich Plasma Preparation
Biological · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2035
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 11:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Maternal and Child Health Through Point-of-care STI Testing

NCT07290439
View directory record Official record
Conditions
Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginalis Vaginitis, Sexually Transmitted Infection
Interventions
Point-of-care STI tests, Standard of care STI testing
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
Female only
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Phase 1 Interventional

T Cell Effector and Regulatory Mechanisms in Asthma

NCT01612936
View directory record Official record
Conditions
Asthma, Allergies
Interventions
Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage, PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)
Biological · Procedure
Lead sponsor
Andrew D. Luster, M.D.,Ph.D.
Other
Eligibility
18 Years to 50 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 22, 2026, 11:41 PM EDT
Active, not recruiting No phase listed Observational

Alpha-1 Antitrypsin Deficiency Adult Liver Study

NCT02014415
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
Liver Biopsy (Biopsy Group Only)
Procedure
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
San Diego, California • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Not applicable Interventional

COVID-19 Plasma Collection

NCT04344015
View directory record Official record
Conditions
COVID-19
Interventions
Plasma Donation
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 22, 2026, 11:41 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

NCT00876915
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism
Interventions
dalteparin injection
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Sacramento, California • Buffalo, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 22, 2026, 11:41 PM EDT
Recruiting No phase listed Observational

Metastatic Leiomyosarcoma Biomarker Protocol

NCT05653388
View directory record Official record
Conditions
Leiomyosarcoma
Interventions
Plasma Collection
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Santa Monica, California • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 22, 2026, 11:41 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development

NCT04956445
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
Tulane University
Other
Eligibility
6 Months to 120 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 22, 2026, 11:41 PM EDT
Active, not recruiting No phase listed Observational

Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.

NCT05634512
View directory record Official record
Conditions
Hematopoietic Cell Transplantation, Mucopolysaccharidosis Type I
Interventions
Laronidase therapy and a stem cell transplant
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
0 Years to 3 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

Pragmatic, Randomized Optimal Platelet and Plasma Ratios

NCT01545232
View directory record Official record
Conditions
Trauma
Interventions
1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
15 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 22, 2026, 11:41 PM EDT
Completed No phase listed Observational Results available

Evaluation of Long-term Buprenorphine Plasma Exposure

NCT03752528
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Blood sample collection, Urine sample collection
Diagnostic Test
Lead sponsor
Indivior Inc.
Industry
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
11
States / cities
Hamilton, Alabama • Tampa, Florida • Prairie Village, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00425386
View directory record Official record
Conditions
Kidney Cancer
Interventions
erlotinib hydrochloride, sunitinib malate, biopsy
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Portland, Oregon • Salem, Oregon
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 22, 2026, 11:41 PM EDT
Completed No phase listed Observational

Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT01295489
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
9
States / cities
Hinsdale, Illinois • Springfield, Illinois • Ames, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

Platelet Rich Plasma Injection in Pilon Fractures

NCT02481869
View directory record Official record
Conditions
Fracture
Interventions
Arthrocentesis/PRP, Arthrocentesis/Saline
Biological · Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 22, 2026, 11:41 PM EDT
Terminated Phase 1 Interventional

Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Rotator Cuff Tears

NCT01688362
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Platelet Rich Plasma (PRP), Corticosteroid
Biological · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

NCT01533246
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
linsitinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2015 · Synced Oct 22, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

NCT02761057
View directory record Official record
Conditions
Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Crizotinib, Savolitinib, Sunitinib Malate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
586
States / cities
Anchorage, Alaska • Kingman, Arizona • Fort Smith, Arkansas + 361 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 22, 2026, 11:41 PM EDT
Completed No phase listed Observational

Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma

NCT00620139
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 22, 2026, 11:41 PM EDT